Stage III oesophageal adenocarcinoma represents a challenging point in the disease journey, where cancer has spread more extensively within the oesophagus and nearby tissues, but treatment still offers hope for improved outcomes and quality of life.

Understanding Treatment Goals in Advanced Oesophageal Cancer

When someone receives a diagnosis of stage III oesophageal adenocarcinoma, the focus of treatment shifts toward a combination of goals that work together to improve both length and quality of life. At this stage, the cancer has grown beyond the inner layers of the oesophagus and may have reached nearby structures or lymph nodes, but has not yet spread to distant organs^[2]. Treatment aims to control the disease, reduce the size of tumours, relieve symptoms such as difficulty swallowing and pain, and when possible, remove cancerous tissue entirely through surgery.

The approach to treating stage III oesophageal adenocarcinoma depends heavily on each patient’s individual circumstances. Doctors consider the precise location and size of the tumour, how many nearby lymph nodes contain cancer cells, the patient’s overall health and fitness for surgery, and whether other medical conditions might affect treatment tolerance^[6]. Some patients may be healthy enough to undergo intensive treatment including surgery, while others may benefit more from therapies that focus on symptom control and maintaining quality of life.

Modern cancer care recognizes that treating stage III disease requires a team of specialists working together. This typically includes medical oncologists who manage chemotherapy and newer drug treatments, radiation oncologists who plan and deliver radiation therapy, surgeons who perform operations when appropriate, and nutritionists who help patients maintain adequate nutrition during treatment^[9]. Additional support from palliative care specialists can help manage complex symptoms and provide emotional and practical support throughout the treatment journey.

There are established treatments that medical societies around the world recommend for this stage of oesophageal cancer. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative approaches that may one day become standard care. Understanding both current treatment options and emerging therapies helps patients and families make informed decisions about care.

Standard Treatment Approaches for Stage III Oesophageal Adenocarcinoma

Chemoradiation, which means giving chemotherapy and radiation therapy at the same time, forms the backbone of treatment for many people with stage III oesophageal adenocarcinoma. This combined approach works better than either treatment alone because the chemotherapy drugs make cancer cells more sensitive to radiation, while the radiation targets the tumour directly^[6]. Doctors often use this combination before surgery to shrink the tumour, making it easier to remove. This is called neoadjuvant therapy. In some cases, chemoradiation may be given after surgery to eliminate any remaining cancer cells, known as adjuvant therapy.

The chemotherapy drugs most commonly used for stage III disease include combinations of several active substances. Cisplatin paired with either fluorouracil or capecitabine represents a frequently chosen regimen. Other combinations include carboplatin with paclitaxel, or more complex three-drug combinations such as epirubicin, cisplatin, and fluorouracil^[6]. These drugs work by interfering with cancer cells’ ability to grow and divide. Cisplatin and carboplatin are platinum-based drugs that damage the DNA inside cancer cells. Fluorouracil and capecitabine block the production of building blocks that cancer cells need to make new DNA. Paclitaxel prevents cancer cells from dividing by interfering with structures inside the cell that help separate chromosomes during cell division.

The duration of chemotherapy treatment varies depending on whether it is given before or after surgery. Typical courses before surgery last between six and twelve weeks, while post-surgery chemotherapy may continue for several months^[9]. Radiation therapy is usually delivered five days per week over a period of five to six weeks when combined with chemotherapy. The radiation beams are carefully aimed at the tumour and nearby lymph nodes while trying to minimize damage to healthy tissue.

Surgery plays a critical role for patients with stage III disease who are healthy enough to undergo a major operation. The standard surgical procedure, called an oesophagectomy, involves removing part or most of the oesophagus along with nearby lymph nodes^[9]. Surgeons then reconstruct the digestive tract by pulling up the stomach or using a section of intestine to replace the removed oesophagus. In many centres, this surgery is now performed using minimally invasive or robotic-assisted techniques, which may result in less pain and faster recovery compared to traditional open surgery. However, oesophagectomy remains a complex operation that requires several hours to complete and involves significant risks including infection, bleeding, and leakage at the sites where organs are reconnected.

Recovery from oesophageal surgery typically requires a hospital stay of one to two weeks, followed by several months of gradual healing at home. Patients face permanent changes to their digestive system. Because the stomach is smaller or reshaped, people must eat smaller, more frequent meals—often five to six small meals per day instead of three large ones^[9]. Weight loss is common, and careful attention to nutrition becomes essential. Some patients experience dumping syndrome, where food moves too quickly from the stomach into the small intestine, causing nausea, cramping, and diarrhea.

For patients who are not healthy enough to undergo surgery or who choose not to have an operation, chemoradiation can be given as the main treatment with the goal of controlling the cancer for as long as possible^[6]. This approach may not eliminate all cancer cells, but it can significantly shrink tumours, relieve symptoms, and improve quality of life. Some patients live for extended periods with well-controlled disease using this strategy.

Targeted Therapies: Precision Medicine for Stage III Disease

Targeted therapy represents a more precise approach to cancer treatment, using drugs that attack specific molecules on or inside cancer cells. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapies are designed to interfere with particular proteins or pathways that cancer cells rely on to grow and survive. For patients with stage III oesophageal adenocarcinoma, targeted therapies are usually combined with chemotherapy to enhance effectiveness.

One important targeted therapy is trastuzumab, which is used for tumours that test positive for a protein called HER2. HER2 is a receptor on the cell surface that, when overactive, drives cancer growth. Trastuzumab is a monoclonal antibody—a laboratory-made protein that attaches to HER2 receptors and blocks signals that tell cancer cells to grow^[6]. Not all oesophageal adenocarcinomas have high levels of HER2, so testing tumour tissue is necessary to determine if this treatment is appropriate. When combined with chemotherapy drugs like cisplatin and fluorouracil or capecitabine, trastuzumab can improve outcomes for patients whose tumours are HER2-positive.

Another targeted therapy called ramucirumab works differently. This monoclonal antibody blocks a substance called vascular endothelial growth factor (VEGF), which tumours use to stimulate the growth of new blood vessels^[6]. Without new blood vessels to bring oxygen and nutrients, cancer cells struggle to grow and spread. Ramucirumab is given in combination with paclitaxel chemotherapy.

A newer targeted therapy called zolbetuximab has recently become available for some patients with advanced oesophageal cancer. This monoclonal antibody attaches to a protein called Claudin 18.2 found on the surface of some oesophageal cancer cells, helping to stop their growth^[6]. It can be used as a first treatment in combination with chemotherapy for cancer that cannot be removed by surgery or has spread.

Targeted therapies generally cause different side effects than traditional chemotherapy. Trastuzumab can sometimes affect the heart, so doctors monitor heart function during treatment. Ramucirumab may cause high blood pressure and, rarely, bleeding problems. Most targeted therapies are given intravenously in the clinic or hospital, similar to chemotherapy infusions.

Immunotherapy: Harnessing the Immune System

Immunotherapy represents one of the most exciting advances in cancer treatment over the past decade. Instead of directly attacking cancer cells, immunotherapy helps the patient’s own immune system recognize and destroy cancer. Normally, the immune system patrols the body looking for abnormal cells, but cancer cells often find ways to hide from immune surveillance or turn off immune responses. Immunotherapy drugs can remove these brakes and allow the immune system to work properly again.

The most commonly used immunotherapy drugs for stage III oesophageal adenocarcinoma are called checkpoint inhibitors. These drugs block proteins that cancer cells use to turn off immune responses. Pembrolizumab is one such drug that may be offered in combination with cisplatin and fluorouracil as a first treatment for patients with certain types of oesophageal tumours^[6]. For HER2-negative adenocarcinoma tumours at the gastroesophageal junction (where the oesophagus meets the stomach), pembrolizumab can be combined with chemotherapy. It can also be used with cisplatin, fluorouracil, and trastuzumab for HER2-positive tumours.

Nivolumab is another checkpoint inhibitor that may be offered in several situations. If cancer remains after a patient has completed neoadjuvant chemoradiation and surgery, nivolumab may be given to reduce the risk of cancer returning^[6][9]. This approach is supported by emerging research showing benefits when immunotherapy is used after standard treatment. Nivolumab can also be combined with chemotherapy (either cisplatin and fluorouracil or carboplatin and fluorouracil) for tumours at the gastroesophageal junction or adenocarcinoma tumours. Some patients receive nivolumab as a monthly intravenous infusion for up to one year following their other treatments.

A drug called ipilimumab may be offered in combination with nivolumab for some patients^[6]. Ipilimumab blocks a different checkpoint protein than nivolumab, and using both together can sometimes produce stronger immune responses against cancer.

Immunotherapy side effects differ substantially from chemotherapy because they result from an overactive immune system rather than direct cell damage. Common problems include fatigue, skin rashes, diarrhea, and inflammation of various organs such as the lungs, liver, or intestines. These side effects can range from mild to severe, and in rare cases may become life-threatening if not recognized and treated promptly. However, many patients tolerate immunotherapy better than traditional chemotherapy, experiencing fewer nausea and blood count problems.

Innovative Treatments Being Tested in Clinical Trials

Clinical trials are carefully designed research studies that test new treatments or new combinations of existing treatments to determine if they are safe and effective. For patients with stage III oesophageal adenocarcinoma, clinical trials may offer access to promising therapies that are not yet available as standard treatment. Understanding the phases of clinical trials helps patients evaluate whether participation might be appropriate.

Phase I trials test a new treatment in a small group of people for the first time to evaluate safety, determine safe dosage ranges, and identify side effects. These trials focus primarily on safety rather than whether the treatment works against cancer. Phase II trials give the treatment to a larger group of people to see if it is effective and to further evaluate safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to determine which approach produces better outcomes.

Several innovative approaches are currently being explored in clinical trials for oesophageal cancer, though specific trial availability varies by location and time. New immunotherapy combinations are being tested to see if using multiple checkpoint inhibitors together, or combining immunotherapy with targeted therapies or newer chemotherapy drugs, produces better results than current approaches. Researchers are studying the optimal timing and duration of immunotherapy—for example, whether giving it before surgery provides better outcomes than giving it afterward.

Novel targeted therapies directed at newly discovered molecules on cancer cells are entering early-phase trials. Scientists continue to identify proteins and pathways that oesophageal cancer cells depend on, creating opportunities to develop drugs that specifically interfere with these targets. Some trials are testing drugs that attack multiple targets simultaneously, potentially making it harder for cancer cells to develop resistance.

Researchers are also investigating whether treatment can be tailored based on the specific genetic mutations found in each patient’s tumour. This approach, called precision oncology, involves testing tumour tissue for a wide range of genetic changes and then selecting treatments that target those specific abnormalities. While this strategy has shown promise in some cancer types, it is still being refined for oesophageal cancer.

Clinical trials for oesophageal cancer are conducted in many locations worldwide, including major cancer centres in the United States, Europe, and other regions. Eligibility for trials depends on many factors including the stage and characteristics of the cancer, previous treatments received, overall health status, and specific criteria set by each study. Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks of participation.

Most Common Treatment Methods

• Chemoradiation Therapy
  • Combination of chemotherapy drugs (such as cisplatin with fluorouracil or capecitabine) given at the same time as radiation therapy
  • Used before surgery to shrink tumours (neoadjuvant therapy) or after surgery to eliminate remaining cancer cells (adjuvant therapy)
  • Can be given as main treatment for patients who cannot or choose not to have surgery
  • Treatment typically lasts six to twelve weeks
• Chemotherapy
  • Multiple drug combinations including cisplatin, carboplatin, fluorouracil, capecitabine, paclitaxel, epirubicin, oxaliplatin, and others
  • May be given alone before surgery or combined with targeted therapy or immunotherapy
  • Works by interfering with cancer cell growth and division
  • Administered through intravenous infusion, typically in cycles
• Surgery (Oesophagectomy)
  • Removal of part or most of the oesophagus along with nearby lymph nodes
  • Digestive tract reconstruction using stomach or intestinal tissue
  • May be performed using minimally invasive or robotic-assisted techniques
  • Appropriate for patients healthy enough to undergo major surgery
  • Requires permanent dietary and lifestyle adjustments
• Targeted Therapy
  • Trastuzumab for HER2-positive tumours, combined with chemotherapy
  • Ramucirumab to block blood vessel formation, given with paclitaxel
  • Zolbetuximab targeting Claudin 18.2 protein, combined with chemotherapy
  • Usually given as intravenous infusions
• Immunotherapy
  • Pembrolizumab combined with chemotherapy as first-line treatment for certain tumour types
  • Nivolumab after neoadjuvant therapy and surgery if cancer remains, or combined with chemotherapy
  • Ipilimumab in combination with nivolumab for some patients
  • Works by helping the immune system recognize and attack cancer cells
  • May be given for up to one year following other treatments